Pharmacokinetic and Pharmacodynamic Profile of Epinephrine Nasal Spray Versus Intramuscular Epinephrine Autoinjector in Healthy Adults.

Autor: Greenhawt M; Section of Allergy and Immunology, Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Denver, Colo. Electronic address: Matthew.Greenhawt@childrenscolorado.org., Lieberman J; The University of Tennessee Health Science Center, Memphis, Tenn., Blaiss M; Department of Pediatrics, Medical College of Georgia, Augusta, Ga., Bernstein DI; Division of Immunology and Allergy, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, Cincinnati, Ohio., Oppenheimer J; Department of Internal Medicine, University of Medicine and Dentistry of New Jersey-Rutgers New Jersey Medical School, Newark, NJ., DuBuske L; Department of Medicine, The George Washington University Hospital, Washington, DC., Fleischer D; Section of Allergy and Immunology, Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Denver, Colo., Dworaczyk DA; Bryn Pharma, LLC, Lebanon, NJ.

Publikováno v: The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2024 Dec; Vol. 12 (12), pp. 3274-3282.e2. Date of Electronic Publication: 2024 Oct 10.

A 13.2 mg epinephrine intranasal spray demonstrates comparable pharmacokinetics, pharmacodynamics, and safety to a 0.3 mg epinephrine autoinjector.

Autor: Dworaczyk DA; Bryn Pharma LLC, Raleigh, NC., Hunt AL; Celerion Inc, Lincoln, Neb., Di Spirito M; Celerion Inc, Lincoln, Neb., Lor M; Celerion Inc, Lincoln, Neb., Dretchen KL; Mesa Science Associates, Frederick, Md., Lamson MJ; Allucent, Cary, NC., Pollock J; Celerion Inc, Lincoln, Neb., Ward T; Celerion Inc, Lincoln, Neb.

Publikováno v: The journal of allergy and clinical immunology. Global [J Allergy Clin Immunol Glob] 2023 Dec 12; Vol. 3 (2), pp. 100200. Date of Electronic Publication: 2023 Dec 12 (Print Publication: 2024).